Cambrex, manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate
The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion, which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.
Juliette White, VP Global External Sourcing, AstraZeneca, said: “Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery. We look forward to a successful collaboration with Cambrex.”
Shawn Cavanagh, COO of Cambrex, said: “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products. We will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand.”